CXCR2 inhibition enables NASH-HCC immunotherapy
J. Leslie, J. B. G. Mackey, T. Jamieson…·Carlin
This study shows that combining CXCR2 inhibition with anti-PD1 therapy enhances immunotherapy response in NASH-HCC by reprogramming tumor-associated neutrophils.